Status:

NOT_YET_RECRUITING

Clareon PanOptix Versus AcrySof PanOptix : Prospective Study Comparing Contrast Sensitivity

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborating Sponsors:

Alcon Research

URC-CIC Paris Descartes Necker Cochin

Conditions:

Cataract and IOL Surgery

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Retrospective, comparative, interventional, randomized, single-center study, contralateral (the patient's 2 eyes will be implanted: 1 CPO and the other APO) Patients presenting for cataract surgery wi...

Detailed Description

Visit at Day3-10: usual follow-up visit, no additional examinations as part of the clinical investigation. Visit at 1 month: usual follow-up visit, no additional examinations as part of the clinical ...

Eligibility Criteria

Inclusion

  • Patients ≥ 18 years of age
  • Patients presenting for cataract surgery in routine clinical practice and eligible for multifocal IOL implantation (toric and non-toric)
  • Patients with grade 2/3 cataract density and comparable visual acuity in both eyes
  • Patient with a pregnancy test (negative pregnancy test), if applicable
  • Patient with signed consent to participate in the study
  • Patient affiliated to a social security scheme or entitled beneficiary

Exclusion

  • Children \< 18 years of age
  • Pregnancy or breast-feeding in progress or planned during the study.
  • History of anterior (cornea, anterior chamber, sulcus) or posterior (uveal, vitreoretinal) segment pathology, including retinal vascular occlusive disease, retinal detachment or peripheral retinal laser photocoagulation, AMD, glaucoma.
  • Any inflammation of the anterior or posterior segment, whatever the etiology, and/or history of any disease with intraocular inflammatory repercussions.
  • Clinically significant corneal pathology (epithelial, stromal and/or endothelial) that could have an impact on visual results.
  • Clinically significant moderate or severe dry eye that could affect study measurements.
  • History of intraocular or corneal surgery (refractive or trauma-related).
  • Presence or history of amblyopia or monofixation syndrome.
  • Subjects with conditions that increase the risk of zonular disruption during the phacoemulsification procedure that may affect the centration or postoperative orientation of the IOL.
  • Any other planned eye surgery, including, but not limited to, limbal relaxing incision (LRI)/astigmatic keratotomy and laser refractive surgery (LASIK).
  • Irregular astigmatism identified by corneal topography
  • Patients under guardianship, curatorship or safeguard of justice, as well as pregnant or breast-feeding women (article L1121-5 of the CSP).1.1
  • Patient under AME

Key Trial Info

Start Date :

September 15 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 15 2026

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT07158177

Start Date

September 15 2025

End Date

October 15 2026

Last Update

September 5 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Assistance Publique - Hôpitaux de Paris, Ophtalomopôle - Hôpital COCHIN

Paris, Île-de-France Region, France, 75014